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INTRODUCTION
NBAS (Neuroblastoma-amplified sequence), also previously referred to as NAG (Neuroblastoma-amplified gene) contains 52 exons, spans 420 kb and is mapped to chromosome 2p24.3 [1] . It was initially identified as a gene co-amplified with the N-myc (MYCN) gene in neuroblastoma cell lines [2] (Wimmer et al., 1999) . NBAS was initially described as a novel factor involved in the nonsense mediated (NMD) decay pathway in human cells, in zebrafish and in nematodes [3, 4] Subsequently, NBAS was also identified as a component of the syntaxin 18 complex, which is involved in Golgi-to-endoplasmic reticulum (ER) retrograde transport [6, 7] ( Aoki et al., 2009; Spang A., 2013) . NBAS is also said to be an important component of the ER tethering complex [8] (Hong WJ and Lev S., 2014) . Using whole exome sequencing, we identified compound heterozygous variants in NBAS in two patients with bone fragility: Patient 1 presented with significant short stature, bone fragility requiring treatment with bisphosphonates, developmental delay and immunodeficiency and was independently investigated for a novel cause of bone fragility (having tested negative for all published variants in OI). Patient 2 was recruited to the Deciphering Developmental Disorders (DDD) study and underwent trio whole exome sequencing.
Homozygous missense variants in NBAS have been implicated in a hereditary short stature syndrome referred to as SOPH syndrome (Short stature; Optic atrophy; Pelger-Huet anomaly) observed in the Yakut Siberian population isolate [9] (Maksimova et al., 2010) . Compound heterozygous mutations in NBAS have also been described in acute onset liver failure [10] ( Haack et al., 2015) . Further reports have suggested a multi-system phenotype [11, 12, 13] (Segarra NG et al., 2015; Capo-Chichi et al., 2015; Staufner et al., 2016) . Bone fragility severe enough to need bisphosphonate therapy has not reported as a feature, so far, in association with NBAS. Therefore, we propose that compound heterozygous mutations in NBAS can account for a significant form of bone fragility and needs to be considered in the differential diagnosis of osteogenesis imperfecta (OI).
CLINICAL REPORT Patient 1:
This 10-year old boy is the second child of healthy, non-consanguineous parents, of North European origin, with no significant family history. He was born by spontaneous breech delivery at 33 weeks gestation following a normal pregnancy, with a birth weight of 1.75kg (9 th centile). He required continuous positive airway pressure ventilation (CPAP) for 24 hours and phototherapy for jaundice. He had recurrent infections and significant problems with his feeding, requiring percutaneous gastrostomy insertion to maintain adequate nutrition.
He had recurrent admissions to hospital with infections including severe recurrent shingles with worsening of liver function during infectious episodes and consequent progressive lymphopenia and hypogammaglobulinaemia requiring immunoglobulin replacement. He was diagnosed with a horizontal nystagmus, bilateral optic atrophy and myopia, needing corrective glasses, but his hearing was reported as normal. He has moderate intellectual disability and growth parameters remain well below the 0.4 th centile. In early childhood, he went on to sustain fractures of his tibia and metatarsals, following minimal trauma and has discoloured teeth. He attends an integrated play school, as he has been diagnosed with an autism spectrum disorder.
On examination at 9-years of age, he was dysmorphic, with proptosis, progeric appearance to his skin, bilateral low-set ears, dentinogenesis imperfecta, and bilateral 5 th finger clinodactyly with bulbous tips to his fingers and toes (Figure 1a-e) . He has a high-pitched voice and growth parameters at 7 years of age were: weight ~ 13.1kg (<0. 
MATERIALS AND METHODS
Patient 1 was recruited into a research project to study atypical forms of OI, to establish genotype: phenotype correlations therein. Ethical approval was obtained from the local regional ethics committee (LREC) to undertake phenotyping and genetic work-up in this group of patients. Patient 2 was recruited to the DDD study.
DNA Sequencing and mutation analysis in Patient 1:
Total genomic DNA was isolated from 2 to 5 ml peripheral blood using standard extraction methods. Whole exome sequencing was performed by Personalis using their ACE Exome Additionally, the full set of variants reported by Personalis was investigated using their annotation. Quality control was carried out using the following hard filters, as recommended by the GATK best practice guidelines when there are exome sequences for less than 30
samples plus an extra filter on genotype quality: for SNVs, QD < 2, MQ < 40, FS > 60, HaplotypeScore > 13, MQRankSum < -12.5, ReadPosRankSum < -8; for Indels, QD < 2, ReadPosRankSum < -20, FS > 200. Population frequencies from the Exome Aggregation Consortium (ExAC, version 0.3) were used in filtering. Only passed ExAC variants were used and alleles at multiallelic sites were left aligned to ensure they could be matched with the patient data. The number of ExAC individuals in a sub-population that are genotyped at a site can be low, meaning that the frequency is estimated with a large error. Therefore, from the ExAC set only variants that had a frequency >5% in any subpopulation (excluding the 'other' population), or of >1% with a total allele count >1000 were retained. These variants were filtered out from the Personalis dataset. Variants reported with a frequency > 1% in any of the 1000 genomes, NHLBI ESP or UK10K cohort populations were also excluded. After filtering, those variants annotated as frameshift, splice site acceptor, splice site donor, or stop gained were extracted and are described as loss of function (LoF) variants. Finally, a larger group of variants annotated within a targeted gene list was compiled, which are described as targeted missense variants. The targeted gene list consisted of genes reported in connection with skeletal dysplasia, identified in GWAS studies to be associated with a change in bone density, implicated in bone metabolism in mouse models, and genes with human phenotype ontology terms relating to increased susceptibility to fracture (HPO:0002659), and totalled approximately 600 genes. The LoF and targeted missense variants were manually reviewed, including looking for compound heterozygotes, to assess whether they might contribute to the patient's phenotype.
DNA Sequencing and mutation analysis in Patient 2:
Trio-based exome sequencing was performed for Patient 2 and his parents as part of the DDD study, as previously described [14, 15] 
Microscopic analysis of collagen in cultured fibroblasts in Patient 1:
NBAS patient 1 cultured fibroblasts and control sample were grown for 3 days in 96 well plates, fixed and stained with anti-Col1A1 antibody (green) and Hoechst (blue) and imaged using a high content microscope. Since NBAS has been proposed to function in the NMD pathway and Golgi-ER transport, the effect on bone fragility could be attributed to either pathway in isolation, or alternatively to a combination of both. We propose three possible models to explain how NBAS variants give rise to phenotypes and human disease based on the cell studies (WB and high content microscopy) and EM findings; 1) due to a compromised Golgi-ER retrograde transport, 2)
RESULTS
due to an NMD phenotype, 3) a dual role i.e. a compromised Golgi-ER transport indirectly affecting NMD.
Homozygous missense variants c.5741G>A(p.Arg1914His) in NBAS were reported as being 
SUMMARY
Bone fragility, severe enough to need therapy in childhood, has not been previously reported as a feature associated with variants in NBAS. Therefore, we hypothesise that compound heterozygous variants in NBAS accounts for bone fragility and is a novel cause of Osteogenesis Imperfecta (OI). The increasing evidence pointing to a role for NBAS in liver, immune and connective tissue coupled with its extreme phenotypic variability make understanding NBAS function important.
FIGURE LEGENDS
Figure 1a-e: 1a-c: Facial features as an infant and aged >1, 2 and 9 years showing grey sclerae, broad forehead, bilateral low-set ears, proptosis and progeric appearance; 1d-e:
Hands and feet at 2-years of age. 
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